Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?
作者信息
Marchetti Claudia, Rosati Andrea, Scambia Giovanni, Fagotti Anna
机构信息
Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Catholic University of the Sacred Heart, Rome, Italy.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S372. doi: 10.21037/atm.2019.12.94.
Abstract
摘要
相似文献
1
Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?
Ann Transl Med. 2019 Dec;7(Suppl 8):S372. doi: 10.21037/atm.2019.12.94.
2
Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:154-160. doi: 10.1016/j.ejogrb.2018.06.036. Epub 2018 Jun 20.
3
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Clin Exp Metastasis. 2019 Oct;36(5):433-439. doi: 10.1007/s10585-019-09982-1. Epub 2019 Jul 3.
4
Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.
Ann Surg Oncol. 2015 Feb;22(2):649-54. doi: 10.1245/s10434-014-4011-0. Epub 2014 Aug 26.
5
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Cancer. 2006 May 1;106(9):1933-9. doi: 10.1002/cncr.21845.
6
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Ann Surg Oncol. 2015 Mar;22(3):987-93. doi: 10.1245/s10434-014-4049-z. Epub 2014 Sep 12.
7
Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):428-32. doi: 10.1016/j.jmig.2014.11.008. Epub 2014 Nov 26.
8
Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience.
J Minim Invasive Gynecol. 2018 May-Jun;25(4):644-650. doi: 10.1016/j.jmig.2017.10.024. Epub 2017 Nov 13.
9
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.
10
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Int J Cancer. 2015 Feb 1;136(3):699-708. doi: 10.1002/ijc.29011. Epub 2014 Jun 17.
引用本文的文献
1
Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
2
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Ann Transl Med. 2020 Oct;8(20):1295. doi: 10.21037/atm-20-5741.
3
Surgery chemotherapy for ovarian cancer recurrence: what is the best treatment option.
Gland Surg. 2020 Aug;9(4):1112-1117. doi: 10.21037/gs-20-326.
4
Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature.
Gland Surg. 2020 Aug;9(4):1092-1101. doi: 10.21037/gs-20-357.
5
Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer.
Ann Transl Med. 2020 Jun;8(12):752. doi: 10.21037/atm-20-4072.
本文引用的文献
1
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Gynecol Oncol. 2019 Dec;155(3):400-405. doi: 10.1016/j.ygyno.2019.09.020. Epub 2019 Oct 9.
2
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
3
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Am J Obstet Gynecol. 2019 Dec;221(6):625.e1-625.e14. doi: 10.1016/j.ajog.2019.06.009. Epub 2019 Jun 14.
4
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
5
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Ann Surg Oncol. 2018 Nov;25(12):3701-3708. doi: 10.1245/s10434-018-6700-6. Epub 2018 Aug 20.
6
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
7
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
8
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.
9
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
10
The role of secondary surgery in recurrent ovarian cancer.
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.
Zotero 插件